Skip to Main Content

Author Details

Ultan McDermott
Wellcome Sanger Institute
1993
119
59
PMIDPaper TitleJournal TitlePublished Year
36219477Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma.J Pathol2023
35086954Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.Mol Cancer Ther2022
35351890Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.Nat Commun2022
36969743Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.Cancer Res Commun2022
32690604Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.Gut2021
34021238Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxia.Commun Biol2021
33028592In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.Clin Cancer Res2021
32554709ctDNA monitoring using patient-specific sequencing and integration of variant reads.Sci Transl Med2020
35121986Genomics-guided pre-clinical development of cancer therapies.Nat Cancer2020
31743054Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.J Clin Oncol2020
33334013Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer.Cells2020
33205120Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.Patterns (N Y)2020
32878980A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.Sci Transl Med2020
32990596Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.Elife2020
30849372Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.Cell2019
30218636A lentiviral vector-based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma.Pigment Cell Melanoma Res2019
30224339NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.Clin Cancer Res2019
31127149Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.Leukemia2019
31097696Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.Nat Commun2019
30852338Large-scale compound screens and pharmacogenomic interactions in cancer.Curr Opin Genet Dev2019
29170471Steps forward for cancer precision medicine.Nat Rev Drug Discov2018
30166531Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.Cell Death Dis2018
30202034An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.Sci Rep2018
30139972The germline genetic component of drug sensitivity in cancer cell lines.Nat Commun2018
30262817Cancer cell lines as patient avatars for drug response prediction.Nat Genet2018
30286710XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.BMC Bioinformatics2018
30299440Corrigendum: High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.Sci Data2018
29634948The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils.Cancer Cell2018
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29713020Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich.Sci Rep2018
29061644Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.Clin Cancer Res2018
29157092Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Cell Cycle2018
29345617Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.Elife2018
27740635A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Leukemia2017
28495283Molecular diagnoses of century-old childhood tumours.Lancet Oncol2017
28179366Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.Genome Res2017
28092685Precision oncology for acute myeloid leukemia using a knowledge bank approach.Nat Genet2017
28945760Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PLoS Genet2017
28972570High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.Sci Data2017
28854368Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.Cell Rep2017
28643781Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.Nat Commun2017
28767654Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.PLoS One2017
28865260Societal challenges of precision medicine: Bringing order to chaos.Eur J Cancer2017
28736238The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens.Cell Chem Biol2017
26923330Targeting the RB-E2F pathway in breast cancer.Oncogene2016
27615322Mutational signatures of ionizing radiation in second malignancies.Nat Commun2016
27876821Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy.Sci Rep2016
27760321A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Cell Rep2016
27804975Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.Nat Commun2016
27397505A Landscape of Pharmacogenomic Interactions in Cancer.Cell2016
  • 1 - 50 of 119

Recommended Authors

Raunak Shrestha
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 3
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 22
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 13
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 24
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 23
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 8
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 5
Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
Career Start Year 2005
Number of shared co-authors 10
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 12
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 3
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 34
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 9
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 14
Nikhil Wagle
Dana-Farber Cancer Institute
Career Start Year 2000
Number of shared co-authors 12
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 19
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 3
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 48
Barbara A Weir
Janssen Research and Development LLC
Career Start Year 1997
Number of shared co-authors 14
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 21
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 15
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 20
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 1
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 26
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 3
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 27
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 7
William C Reinhold
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 14

Collaborators

Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 35
Michael R Stratton
Wellcome Sanger Institute
Co-authored papers 18
Cyril H Benes
Co-authored papers 16
Peter J Campbell
Wellcome Sanger Institute
Co-authored papers 16
Adam Butler
Wellcome Sanger Institute
Co-authored papers 14
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 12
Patrick S Tarpey
Wellcome Trust Sanger Institute
Co-authored papers 12
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Co-authored papers 12
Peter Van Loo
The Francis Crick Institute
Co-authored papers 11
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 11
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Inigo Martincorena
Wellcome Sanger Institute
Co-authored papers 11
Serena Nik-Zainal
Early Cancer Institute, University of Cambridge
Co-authored papers 10
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 10
Colin S Cooper
Norwich Medical School, University of East Anglia
Co-authored papers 10
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 9
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 9
Christopher S Foster
The Institute of Cancer Research
Co-authored papers 9
Jon Teague
Wellcome Sanger Institute
Co-authored papers 9
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 9
Keiran Raine
Wellcome Sanger Institute
Co-authored papers 9
Sarah O'Meara
Clinical Research Facility, Mercy University Hospital
Co-authored papers 8
Andrew Menzies
Wellcome Sanger Institute
Co-authored papers 8
David J Adams
Wellcome Sanger Institute
Co-authored papers 8
Adrienne M Flanagan
University College London, UCL Cancer Institute
Co-authored papers 8
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Co-authored papers 8
Manasa Ramakrishna
Co-authored papers 8
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 8
Claire Hardy
Wellcome Sanger Institute
Co-authored papers 7
Hayley C Whitaker
University College London
Co-authored papers 7
Release 1.2